<i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.

Coupez, Dahna; Hulo, Pauline; Touchefeu, Yann; Denis, Marc G; Bennouna, Jaafar

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.

Coupez, Dahna; Hulo, Pauline; Touchefeu, Yann; Denis, Marc G; Bennouna, Jaafar.

Afiliación

Coupez D; Medical Oncology Department, University Hospital of Nantes, France.
Hulo P; Medical Oncology Department, University Hospital of Nantes, France.
Touchefeu Y; Medical Oncology Department, University Hospital of Nantes, France.
Denis MG; Institut des Maladies de l'Appareil Digestif, University Hospital of Nantes, France.
Bennouna J; Department of Biochemistry, Centre Hospitalier Universitaire Nantes, Nantes, France.

Expert Opin Biol Ther ; 21(10): 1325-1334, 2021 10.

Article en En | MEDLINE | ID: mdl-34378483

Asunto(s)

Antineoplásicos/uso terapéutico; Neoplasias Colorrectales; Proteínas Proto-Oncogénicas p21(ras); Biomarcadores de Tumor; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/genética; Humanos; Mutación; Medicina de Precisión; Proteínas Proto-Oncogénicas p21(ras)/genética

Palabras clave

Colorectal cancer; KRAS inhibitors; RAS mutations; SHP2; SOS1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Proteínas Proto-Oncogénicas p21(ras) / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Expert Opin Biol Ther Asunto de la revista: BIOLOGIA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google